ArticleMetabolomics : Official journal of the Metabolomic Society2025
Metabolomic profiling reveals distinct lipid signatures in progressive versus stable fibrotic lung disease.
Article in Metabolomics : Official journal of the Metabolomic Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Analysis of body composition with bioelectrical impedance analysis in different subtypes of pulmonary fibrosis.Scientific reports · 2026Article
- Distinct Metabolic Signatures Linked to High-Resolution Computed Tomography Radiographic Phenotypes in Stable and Progressive Fibrotic Lung Disease.Metabolites · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare the metabolomic profile differences between ILD (interstitial lung disease) and chronic obstructive pulmonary disease (COPD) controls, and to distinguish profiles between progressive and stable idiopathic pulmonary fibrosis (IPF)/ILD subjects.
methodsThis single-center prospective study enrolled n = 71 (progressive IPF/ILD: n = 33, stable IPF/ILD: n = 27, COPD: n = 11) participants between December 2021 and October 2022. Metabolite quantification was performed using the liquid chromatography-mass spectrometry (LC-MS platform), and nuclear magnetic resonance spectroscopy (
results715 metabolites were accurately quantified to investigate (a) differences between the combined groups of stable and progressive idiopathic pulmonary fibrosis IPF/ILD and COPD controls, and (b) differences between progressive IPF/ILD and stable IPF/ILD controls. The most notable metabolites distinguishing fibrotic lung disease (both stable and progressive IPF/ILD) from COPD were glycerolipids (GL). Enrichment analysis of IPF/ILD versus COPD revealed significant disruptions in lipid metabolic pathways, particularly glycerophospholipids, and sphingolipids (false discovery rate FDR q-value < 0.05). In addition, significant disruptions in TG species were found in progressive IPF/ILD with enrichment analysis revealing dysregulation of metabolic pathways associated with glycerophospholipids (FDR q-value < 0.05).
conclusionThese findings emphasize the dysregulation of lipid metabolism in fibrotic lung diseases, involving glycerolipids, glycerophospholipids, and sphingolipids. The distinct lipid alterations identified through metabolomic profiling provide valuable insight into lipid metabolism in IPF/ILD, warranting further research to explore their potential as biomarkers.
Indexed as
Identifiers
41139176What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.